Applications for Phase 3 clinical trials of Deki Pharmaceutical SVd combination therapy for rrMM were accepted by NMPA

The trial, a phase 3, randomized, open multi-center study, aimed at comparing the effectiveness and safety of ATG-010, boroniczomi and dexamisso (SVd) treatments with boroniczomi and dexamisson (Vd) treatments in adult patients with recurring recurring multiple myeloma in China who had previously received 1-3 treatment options.
trial is expected to include 150 patients who will be treated with SVd and Vd at random on a 2:1 scale.
ATG-010 is the first and only oral selective nuclear output inhibitor (SINE) of its kind and the first and only FDA-approved drug for the treatment of multiple myeloma and diffuse large B-cell lymphoma.
Deqi Pharmaceuticals has conducted a Phase 2 registered clinical trial (code-named MARCH) in China for the treatment of rrMM patients with ATG-010, with the full number expected to be completed by the end of 2020.
note: There are deletions in the original text